Seminars in Oncology
Volume 34, Issue 2 , Pages 129-134 , April 2007

Multimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Tumors

References 

  1. Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol. 1996;156:1286–1287
  2. Waehre H, Ous S, Klevmak B, et al. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer. 1993;72:3044–3051
  3. Houseset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: A prospective study. J Clin Oncol. 1993;1:2150–2157
  4. Sauer R, Birkenhake S, Kuhn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncolo Biol Phys. 1998;40:121–127
  5. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy and Oncology Group 89-03. J Clin Oncol. 1998;16:3576–3583
  6. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60:62–68
  7. Solsana E, Iberra I, Ricos JV, et al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: Prospective study. J Urol. 1992;147:1513–1515
  8. Herr HW. Conservative management of muscle infiltrating bladder cancer: Prospective experience. J Urol. 1987;138:1162–1163
  9. Dunst J, Sauer R, Schrott M, et al. Organ-sparing treatment of advanced bladder cancer: A 10-year experience. Int J Radiat Oncol Biol Phys. 1994;30:261–266
  10. Dunst J, Rodel C, Zietman A, et al. Bladder preservation in muscle invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol. 2001;20:24–32
  11. Gospodarowicz M, Hawkins G, Rawlings J, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis. J Urol. 1989;142:1448–1453
  12. Duncan W, Quilty PM. The results of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage x-ray therapy. Radiother Oncol. 1986;7:299–310
  13. Shipley WU, Rose MA. Bladder cancer: The selection of patients for treatment by full dose irradiation. Cancer. 1985;55:2278–2284
  14. Miller LS. Bladder cancer: Superiority of preoperative radiation in cystectomy in clinical stage B2 and C. Cancer. 1977;39:973–980
  15. Horwich A, Pendlebur S, Dearnaley D. Organ conservation in bladder cancer. Eur J Cancer. 1995;31(suppl 6):208–209
  16. Sell A, Jakobsen A, Nerstrom B, et al. Treatment of advanced bladder cancer category T2, T3, and T4a (A randomized multicenter study of preoperative radiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor). Scand J Urol Nephrol. 1991;138(suppl):193–201
  17. Horwich A, Dearnaley D, Huddart R, et al. A randomized trial of accelerated radiotherapy for localized invasive bladder cancer. Radiother Oncol. 2005;75:34–43
  18. Shipley W, Zietman A, Kaufman D, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria invasive bladder cancer and who are cystectomy candidates—The Massachusetts General Hospital and Radiation Therapy Group experiences. Semin Radiat Oncol. 2004;15:36–41
  19. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and pre-operative or definitive radiation. J Clin Oncol. 1996;14:2901–2907
  20. Shipley WU, Kaufman DS, Tester WJ, et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer. 2003;97(suppl 8):2115–2119
  21. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG 85-12. Int J Radiat Oncol Biol Phys. 1993;25:783–790
  22. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-FU followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5:471–476
  23. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of RTOG phase III trial 8802. J Clin Oncol. 1996;14:119–126
  24. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48:202–206
  25. Kaufman D, Winter A, Shipley W, et al. Muscle invading bladder cancer, RTOG protocol 99-06: Initial report of phase I/II trial of selective bladder-conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy. J Clin Oncol. 2005;23:397s;(abstr 4506)
  26. Chakravarti A, Winter K, Wu C, et al. Expression of the epidermal growth factor receptor (EGFR) and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the RTOG. Int J Radiat Oncol Biol Phys. 2005;62:309–317
  27. Kent E, Sandler H, Montie J, et al. Combined modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of phase I trial. J Clin Oncol. 2004;22:2540–2545
  28. Herman J, Smith DC, Montie J, et al. Prospective quality of life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology. 2004;64:69–73
  29. Sangar V, McBain C, Lyons J, et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005;61:420–425
  30. Salminen E. Recurrence and treatment of urinary bladder cancer after failure in radiotherapy. Cancer. 1990;66:2341–2345
  31. Henningsohn L, Wijstrom H, Dickman P, et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 1991;22:111–117
  32. Micaelson D, Zietman A. Invasive bladder cancer: The role of bladder preserving therapy. In: Educational Brochure ASCO. 2003;p. 457–465
  33. Zietman AL, Sacco DE, Skowronki UE, et al. Organ conservation as an alternative to radical cystectomy for invasive bladder cancer: Urodynamic and quality of life evaluation of patients treated by trimodality therapy. Int J Radiat Oncol Biol Phys. 2002;54(suppl):62
  34. Cauvet B, Lagrange JL, Geoffrois L, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer (Preliminary results of a French multicenter prospective study). Int J Radiat Oncol Biol Phys. 2003;57(suppl):177
  35. Zietman AL, Shipley WU, Kaufman DS, et al. Organ conserving approaches to muscle invasive bladder cancer: Future alternatives to radical cystectomy. Ann Med. 2000;32:34–42
  36. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: Management and consequences of Ta, T1 and Tis recurrence within the retained bladder. Urology. 2001;58:380–385
  37. Pieras E, Palou J, Salvador J, et al. Management and prognosis of transitional cell carcinoma (Superficial recurrence in muscle invasive bladder cancer after bladder preservation). Eur Urol. 2003;44:222–225
  38. Quek M, Stein J, Nichols P, et al. Prognostic significance of lymphvascular invasion of bladder cancer treated with radical cystectomy. J Urol. 2005;174:103–106

PII: S0093-7754(06)00486-6

doi: 10.1053/j.seminoncol.2006.12.009

Seminars in Oncology
Volume 34, Issue 2 , Pages 129-134 , April 2007

Article Tools